Long-term outcomes in patients with congenital adrenal hyperplasia treated with hydrocortisone modified-release hard capsules
Authors:
- Wiebke ArltWAWiebke Arlt
- Aude Brac de la PerrièreAPAude Brac de la Perrière
- Angelica L HirschbergAHAngelica L Hirschberg
- Deborah P MerkeDMDeborah P Merke
- John D C Newell-PriceJNJohn D C Newell-Price
- Alessandro PreteAPAlessandro Prete
- D Aled ReesDRD Aled Rees
- Nicole ReischNRNicole Reisch
- Philippe A TourainePTPhilippe A Touraine
- Hanna BendfeldtHBHanna Bendfeldt
- John PorterJPJohn Porter
- Helen CoopeHCHelen Coope
Open Access
- 17 June 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 76-84
Abstract
Background: Hydrocortisone modified-release hard capsules (MRHC, development name Chronocort) replace the physiological overnight cortisol rise and improve the biochemical control of congenital adrenal hyperplasia (CAH). Aim: This study aims to evaluate long-term safety, tolerability, and efficacy of MRHC. Methods: This is an open-label follow-on study. Results: Ninety-one patients with classic CAH, mean age 37 years, 68% female, 32% male, entered the study and 22 discontinued. Median treatment duration was 4 years (range 0.2-5.8). Median hydrocortisone dose at study entry was 30 mg/day and reduced to 20 mg/day after 24 weeks and stayed stable thereafter until 48 months (P < .0001). Disease control improved on MRHC for the steroid disease markers serum 17-hydroxyprogesterone (17OHP) (P < .03) and androstenedione (A4) (P < .002). After 4 years, the majority of patients had a 17OHP < 4-fold upper limit of normal (ULN) (71%) and an A4 <ULN (90%). Measurement of 17OHP and A4 at 09:00 h and 13:00 h gave similar results. Of the 37 women < 50 years of age who were not on contraceptives over the whole study period, 5 became pregnant (13.5%). Of the men, 13.8% (4/29) had a partner pregnancy. Seven patients had an adrenal crisis with 1 patient reporting 8 of these giving an incidence of 3.9 crises per 100 patient years. Conclusions: Modified-release hard capsule treatment resulted in hydrocortisone dose reduction followed by a stable dose with improved biochemical control associated with fertility. Biochemical control could be reliably monitored by a single blood sample taken between 09:00 and 13:00 h. The incidence of adrenal crises was below that reported previously in patients with CAH.Keywords
Funding Information
- Diurnal Ltd. UK
- Neurocrine UK Ltd.
- intramural research program of the National Institutes of Health
This publication has 26 references indexed in Scilit:
- Frequency of stress dosing and adrenal crisis in paediatric and adult patients with congenital adrenal hyperplasia: a prospective studyEuropean Journal of Endocrinology, 2024
- Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythmDrug Delivery and Translational Research, 2022
- Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiencyEuropean Journal of Pharmaceutical Sciences, 2021
- Modified-Release Hydrocortisone in Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2021
- Real-World Estimates of Adrenal Insufficiency–Related Adverse Events in Children With Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2020
- Congenital Adrenal Hyperplasia Due to 21-Hydroxylase DeficiencyNew England Journal of Medicine, 2020
- Adrenal CrisisNew England Journal of Medicine, 2019
- Treatment and health outcomes in adults with congenital adrenal hyperplasiaNature Reviews Endocrinology, 2013
- Strategies to Prevent Weight Gain in AdultsAmerican Journal of Preventive Medicine, 2013
- An oral multiparticulate, modified‐release, hydrocortisone replacement therapy that provides physiological cortisol exposureClinical Endocrinology, 2013